Halozyme Therapeutics Inc (NASDAQ:HALO)
| 45.04 Delayed Data As of 3:59pm ET |  -0.09 / -0.20%Today’s Change | 31.36 Today|||52-Week Range 52.98 | +12.01% Year-to-Date |
Latest HALO News | Press Releases
No recent news for Halozyme Therapeutics Inc.
Today’s Trading
| Previous close | 45.13 |
| Today’s open | 45.29 |
| Day’s range | 44.08 - 45.51 |
| Volume | 25,420 |
| Average volume (3 months) | 1,113,562 |
| Market cap | $6.7B |
Data as of 3:59pm ET, 08/08/2022
Growth & Valuation
| Earnings growth (last year) | +202.13% |
| Earnings growth (this year) | -26.34% |
| Earnings growth (next 5 years) | +31.00% |
| Revenue growth (last year) | +65.67% |
| P/E ratio | 15.1 |
| Price/Sales | 13.32 |
| Price/Book | 33.81 |
Competitors
| ---- | ||
| CRSPCRISPR Therapeutics ... | -0.01 | -0.01% |
| ARWRArrowhead Pharmaceut... | +1.07 | +2.33% |
| NTLAIntellia Therapeutic... | +0.24 | +0.38% |
Data as of 4:00pm ET, 08/08/2022
Financials
| Next reporting date | August 10, 2022 |
| EPS forecast (this quarter) | $0.47 |
| Annual revenue (last year) | $443.3M |
| Annual profit (last year) | $402.7M |
| Net profit margin | 90.84% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters --, -- |
Forecasts
